Table 2

Demographic and clinical characteristics of patients with SLE and control groups

Lupus (n=82)Control group (n=54)P value
Age, years39.2±10.840,2±14.30.65
BMI, kg/m225.2±4.624.8±5.20.59
Hand grip, kg21.7±4.925.1±6.6<0.001
SMMI*, kg24 (21–26.3)24.4 (21.6–25.9)0.89
SMMI (BMI)*, kg/(kg/m²)0.98±0.181.03±0.330.47
ANA, n77 (93.9)
Anti-dsDNA, IU/µL275 (18–544)
C3, mg/dL72.3 (56–92)
C4, mg/dL11.4 (8.4–15.6)
PGA1 (0–1)
SLEDAI-2K score8 (6–15.2)
Neurological disorder, n (%)10 (12.2)
Articular involvement, n (%)51 (62.2)
Mucocutaneous involvement, n (%)62 (75.6)
Serosal involvement, n (%)9 (11)
Renal involvement, n (%)21 (25.6)
Haematological involvement, n (%)17 (20.7)
Anti-Ro (SS-A) positivity, n (%)30 (36.6)
Anti-La (SS-B) positivity, n (%)10 (12.2)
Anti-Ro52 positivity, n (%)19 (23.2)
Anti-Sm positivity, n (%)13 (15.9)
Anti-RNP positivity, n (%)23 (28)
Anti-dsDNA positivity, n (%)68 (82.9)
  • *Bioimpedance analysis was conducted on 31 patients with SLE (37.8%) and 52 healthy controls (96.3%).

  • anti-dsDNA, anti-double-stranded DNA; BMI, body mass index; PGA, Physician Global Assessment; RNP, ribonucleoprotein; SLEDAI-2K, SLE Disease Activity Index 2000; SMMI, skeletal muscle mass index.